The UK’s medicines regulator on Wednesday said that under-30s in the country will be offered an alternative to the Oxford/AstraZeneca vaccine due to "evolving evidence” linking it to rare blood clots, even as the European Medicines Agency (EMA) concluded a "possible link" between the vaccine and rare clotting.
The Oxford–AstraZeneca Covid-19 vaccine, a version of which is also being used in India, is made from an adenovirus isolated from chimpanzee poop, which has been genetically changed so that it is impossible for it to grow in humans.
Chen added that in the UK, a high proportion of patients have long Covid-19, but reasons for this phenomenon is not clear so far.
The government on Monday revised the interval between two doses of Oxford-AstraZeneca's Covishield vaccine.
The COVID-19 vaccine developed by Oxford University and bio-pharmaceutical major AstraZeneca is safe and works extremely well, UK Prime Minister Boris Johnson said on Tuesday, amid reports that the doses were causing blood clot-related complications.
Data suggests that in the over 80s, a single dose of either vaccine is more than 80 per cent effective at preventing hospitalisation, around 3 to 4 weeks after the jab, PHE said in a statement.
Just one vaccine shot reduces the risk of being hospitalised by Covid-19 by more than 90 per cent, according to new findings, Daily Mail reported.
A three-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a six-week gap, according to a new study which says the first dose can offer up to 76 per cent protection in the months between the two jabs.
Speaking at the daily press briefing, Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, said, "Today, WHO gave emergency use listing to two versions of the Oxford-AstraZeneca vaccine, giving the green light for these vaccines to be rolled out globally through COVAX."
The University of Oxford has launched the first study to assess the safety and immune responses in children and young adults of its coronavirus vaccine.
The COVID-19 vaccine developed by Oxford University and produced by AstraZeneca has shown efficacy against the UK variant of the coronavirus, according to an ongoing study by researchers.
'Aatmanirbharta' implying self-reliance has been named by Oxford Languages as its Hindi word of the year 2020 as it "validated the day-to-day achievements of the countless Indians who dealt with and survived the perils of a pandemic".
The dosing mishap was presented to the trial participants in a letter dated June 8 as an opportunity for University of Oxford researchers to learn how well the vaccine works at different doses. The letter was signed by the trial's chief investigator, Oxford professor Andrew J. Pollard
India will begin administering coronavirus vaccine by January 13, the Union Health Ministry announced at a press briefing on Tuesday.
I or the Samajwadi party never questioned the experts, researchers or scientists. If there are suspicion or some doubts, it is government's responsibility to clarify: SP chief Akhilesh Yadav
Britain begins inoculating its citizens with the AstraZeneca/Oxford vaccine against COVID-19 giving the shot to Brian Pinker, an 82-year-old dialysis patient, at a hospital in Oxford.
In a shift from practices in the U.S. and elsewhere, Britain plans to give people second doses of both vaccines within 12 weeks of the first shot rather than within 21 days, to accelerate immunizations across as many people as quickly as possible.
The Drugs Controller General of India on Sunday gave nod to two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by Bharat Biotech for restricted emergency use.
Poonawalla'' remarks came soon after after India's drugs regulator, Drug Controller General of India (DCGI) approved Covishield for restricted emergency use.
Top News
Latest News
